» Articles » PMID: 36551635

The Tumor Microenvironment of Hepatocellular Carcinoma: Untying an Intricate Immunological Network

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2022 Dec 23
PMID 36551635
Authors
Affiliations
Soon will be listed here.
Abstract

HCC, the most prevalent form of primary liver cancer, is prototypically an inflammation-driven cancer developing after years of inflammatory insults. Consequently, the hepatic microenvironment is a site of complex immunological activities. Moreover, the tolerogenic nature of the liver can act as a barrier to anti-tumor immunity, fostering cancer progression and resistance to immunotherapies based on immune checkpoint inhibitors (ICB). In addition to being a site of primary carcinogenesis, many cancer types have high tropism for the liver, and patients diagnosed with liver metastasis have a dismal prognosis. Therefore, understanding the immunological networks characterizing the tumor microenvironment (TME) of HCC will deepen our understanding of liver immunity, and it will underpin the dominant mechanisms controlling both spontaneous and therapy-induced anti-tumor immune responses. Herein, we discuss the contributions of the cellular and molecular components of the liver immune contexture during HCC onset and progression by underscoring how the balance between antagonistic immune responses can recast the properties of the TME and the response to ICB.

Citing Articles

Inflammation and Immunity in Liver Neoplasms: Implications for Future Therapeutic Strategies.

Kim J, Seki E Mol Cancer Ther. 2024; 24(2):188-199.

PMID: 39365846 PMC: 11794036. DOI: 10.1158/1535-7163.MCT-23-0726.


Surgical Implications for Nonalcoholic Steatohepatitis-Related Hepatocellular Carcinoma.

Anbarasu C, Williams-Perez S, Camp E, Erstad D Cancers (Basel). 2024; 16(16).

PMID: 39199546 PMC: 11352989. DOI: 10.3390/cancers16162773.


Physical activity enhances the effect of immune checkpoint blockade by inhibiting the intratumoral HIF1-α/CEACM1 axis.

Cui W, Cui J, Gong D, Lai Z, Li B J Mol Histol. 2024; 55(5):785-792.

PMID: 39097565 DOI: 10.1007/s10735-024-10230-4.


The Role of microRNAs in Hepatocellular Cancer: A Narrative Review Focused on Tumor Microenvironment and Drug Resistance.

Tavakoli Pirzaman A, Alishah A, Babajani B, Ebrahimi P, Sheikhi S, Moosaei F Technol Cancer Res Treat. 2024; 23:15330338241239188.

PMID: 38634139 PMC: 11025440. DOI: 10.1177/15330338241239188.


Antitumor immunostimulatory activity of the traditional Chinese medicine polysaccharide on hepatocellular carcinoma.

Liu Y, Wu J, Hao H Front Immunol. 2024; 15:1369110.

PMID: 38455058 PMC: 10917928. DOI: 10.3389/fimmu.2024.1369110.


References
1.
Ginhoux F, Guilliams M . Tissue-Resident Macrophage Ontogeny and Homeostasis. Immunity. 2016; 44(3):439-449. DOI: 10.1016/j.immuni.2016.02.024. View

2.
Wu Z, Xu J, Tan J, Song Y, Liu L, Zhang F . Mesenteric adipose tissue B lymphocytes promote local and hepatic inflammation in non-alcoholic fatty liver disease mice. J Cell Mol Med. 2019; 23(5):3375-3385. PMC: 6484337. DOI: 10.1111/jcmm.14232. View

3.
Zakeri N, Hall A, Swadling L, Pallett L, Schmidt N, Diniz M . Characterisation and induction of tissue-resident gamma delta T-cells to target hepatocellular carcinoma. Nat Commun. 2022; 13(1):1372. PMC: 8927126. DOI: 10.1038/s41467-022-29012-1. View

4.
Highton A, Schuster I, Degli-Esposti M, Altfeld M . The role of natural killer cells in liver inflammation. Semin Immunopathol. 2021; 43(4):519-533. PMC: 8260327. DOI: 10.1007/s00281-021-00877-6. View

5.
Suthen S, Lim C, Nguyen P, Dutertre C, Lai H, Wasser M . Hypoxia-driven immunosuppression by Treg and type-2 conventional dendritic cells in HCC. Hepatology. 2022; 76(5):1329-1344. DOI: 10.1002/hep.32419. View